Please login to the form below

Not currently logged in
Email:
Password:

erenumab

This page shows the latest erenumab news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Novartis migraine treatment Aimovig

NICE rejects Novartis migraine treatment Aimovig

A draft 'no' to first-in-class treatment, despite discount. NICE has issued a draft rejection of Novartis’ Aimovig (erenumab), saying the novel migraine prevention treatment is not cost-effective. ... Meindert Boysen, director of the Centre for Health

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics